J Alzheimers Dis. 2021 Feb 17. doi: 10.3233/JAD-210026. Online ahead of print.

ABSTRACT

There is a dire need for due innovative therapeutic modalities to improve outcomes of AD patients. In this study, we tested whether cannabidiol (CBD) improves outcomes in a translational model of familial AD and to investigate if CBD regulates interleukin (IL)-33 and triggering receptor expressed on myeloid cells 2 (TREM2), which are associated with improved cognitive function. CBD was administered to 5xFAD mice, which recapitulate early onset, familial AD. Behavioral tests and immunoassays were used to evaluate cognitive and motor outcomes. Our findings suggest that CBD treatment enhanced IL-33 and TREM2 expression, ameliorated the symptoms of AD, and retarded cognitive decline.

PMID:33612548 | DOI:10.3233/JAD-210026


Source: ncbi

Partage le savoir
Categories: Medical

error: Content is protected !!